share_log

Pacific Biosciences Analyst Ratings

Pacific Biosciences Analyst Ratings

太平洋生物科學分析師評級
Benzinga ·  2023/09/29 06:08
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/29/2023 7.66% Barclays $14 → $9 Maintains Equal-Weight
09/28/2023 31.58% Bernstein → $11 Initiates Coverage On → Outperform
09/26/2023 67.46% Cantor Fitzgerald → $14 Reiterates Neutral → Neutral
08/22/2023 67.46% Cantor Fitzgerald → $14 Reiterates Neutral → Neutral
08/04/2023 55.5% Morgan Stanley $13 → $13 Reiterates Equal-Weight → Equal-Weight
08/03/2023 55.5% Morgan Stanley $12 → $13 Maintains Equal-Weight
06/30/2023 103.35% Goldman Sachs → $17 Initiates Coverage On → Buy
06/05/2023 103.35% Canaccord Genuity $14 → $17 Maintains Buy
05/10/2023 67.46% Barclays → $14 Initiates Coverage On → Equal-Weight
05/04/2023 43.54% Morgan Stanley $10 → $12 Maintains Equal-Weight
05/03/2023 103.35% TD Cowen $15 → $17 Maintains Outperform
05/03/2023 55.5% Cantor Fitzgerald $12 → $13 Maintains Neutral
03/31/2023 79.43% TD Cowen $13 → $15 Upgrades Market Perform → Outperform
01/05/2023 43.54% Scotiabank → $12 Initiates Coverage On → Sector Outperform
11/16/2022 67.46% Canaccord Genuity $12 → $14 Maintains Buy
08/17/2022 -10.29% Piper Sandler $6 → $7.5 Maintains Neutral
05/16/2022 -28.23% Piper Sandler $13 → $6 Maintains Neutral
05/06/2022 67.46% Morgan Stanley $15 → $14 Maintains Equal-Weight
02/16/2022 378.47% Canaccord Genuity $45 → $40 Maintains Buy
09/27/2021 438.28% Canaccord Genuity → $45 Initiates Coverage On → Buy
08/04/2021 390.43% Morgan Stanley $45 → $41 Maintains Equal-Weight
02/12/2021 438.28% Morgan Stanley $12 → $45 Maintains Equal-Weight
02/11/2021 522.01% Piper Sandler $20 → $52 Upgrades Neutral → Overweight
11/04/2020 43.54% Morgan Stanley $7 → $12 Maintains Equal-Weight
11/03/2020 — Piper Sandler Downgrades Overweight → Neutral
10/02/2020 79.43% JP Morgan → $15 Upgrades Neutral → Overweight
10/01/2020 43.54% Piper Sandler $6 → $12 Maintains Overweight
09/09/2020 -16.27% Morgan Stanley → $7 Initiates Coverage On → Equal-Weight
06/02/2020 -40.19% Cantor Fitzgerald → $5 Assumes → Overweight
03/09/2020 -40.19% Cantor Fitzgerald → $5 Assumes → Overweight
10/15/2019 -4.31% Piper Sandler → $8 Upgrades Neutral → Overweight
04/02/2019 -4.31% Stephens & Co. → $8 Downgrades Overweight → Equal-Weight
01/04/2019 — Cowen & Co. Downgrades Outperform → Market Perform
11/12/2018 — Cantor Fitzgerald Downgrades Overweight → Neutral
10/19/2018 -22.25% Cowen & Co. → $6.5 Initiates Coverage On → Outperform
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/29/2023 7.66% 巴克萊 $14→$9 維護 等重
09/28/2023 31.58% 伯恩斯坦 →$11 開始承保 →跑贏大盤
09/26/2023 67.46% 康託·菲茨傑拉德 →$14 重申 中性→中性
2023年08月22日 67.46% 康託·菲茨傑拉德 →$14 重申 中性→中性
08/04/2023 55.5% 摩根士丹利 $13→$13 重申 等重→等重
08/03/2023 55.5% 摩根士丹利 $12→$13 維護 等重
2023/06/30 103.35% 高盛 →$17 開始承保 →購買
06/05/2023 103.35% 卡納科特·格納奇 $14→$17 維護 買
2023年05月10日 67.46% 巴克萊 →$14 開始承保 →等重
05/04/2023 43.54% 摩根士丹利 $10→$12 維護 等重
05/03/2023 103.35% TD Cowen $15→$17 維護 跑贏大盤
05/03/2023 55.5% 康託·菲茨傑拉德 $12→$13 維護 中性
03/31/2023 79.43% TD Cowen $13→$15 升級 市場表現優於→
01/05/2023 43.54% 加拿大豐業銀行 →$12 開始承保 →板塊跑贏大盤
2022年11月16日 67.46% 卡納科特·格納奇 $12→$14 維護 買
2022/08/17 -10.29% 派珀·桑德勒 $6→$7.5 維護 中性
05/16/2022 -28.23% 派珀·桑德勒 $13→$6 維護 中性
05/06/2022 67.46% 摩根士丹利 $15→$14 維護 等重
02/16/2022 378.47% 卡納科特·格納奇 $45→$40 維護 買
09/27/2021 438.28% 卡納科特·格納奇 →$45 開始承保 →購買
08/04/2021 390.43% 摩根士丹利 $45→$41 維護 等重
02/12/2021 438.28% 摩根士丹利 $12→$45 維護 等重
02/11/2021 522.01% 派珀·桑德勒 $20→$52 升級 中性→超重
11/04/2020 43.54% 摩根士丹利 $7→$12 維護 等重
11/03/2020 - 派珀·桑德勒 評級下調 超重→中性
10/02/2020 79.43% 摩根大通 →$15 升級 中性→超重
10/01/2020 43.54% 派珀·桑德勒 $6→$12 維護 超重
09/09/2020 -16.27% 摩根士丹利 →$7 開始承保 →等重
06/02/2020 -40.19% 康託·菲茨傑拉德 →$5 假設 →超重
03/09/2020 -40.19% 康託·菲茨傑拉德 →$5 假設 →超重
2019年10月15日 -4.31% 派珀·桑德勒 →$8 升級 中性→超重
2019年02月04日 -4.31% 斯蒂芬斯公司 →$8 評級下調 超重→等重
2019年04月01日 - 考恩公司 評級下調 跑贏→市場表現
2018年11月12日 - 康託·菲茨傑拉德 評級下調 超重→中性
2018年10月19日 -22.25% 考恩公司 →$6.5 開始承保 →跑贏大盤

What is the target price for Pacific Biosciences (PACB)?

太平洋生物科學公司(PACB)的目標價格是多少？

The latest price target for Pacific Biosciences (NASDAQ: PACB) was reported by Barclays on September 29, 2023. The analyst firm set a price target for $9.00 expecting PACB to rise to within 12 months (a possible 7.66% upside). 15 analyst firms have reported ratings in the last year.

巴克萊銀行於2023年9月29日公佈了太平洋生物科學公司(納斯達克代碼：PACB)的最新目標價。這家分析公司將目標價定為9.00美元，預計PACB將在12個月內上漲(可能上漲7.66%)。過去一年，有15家分析公司公佈了評級。

What is the most recent analyst rating for Pacific Biosciences (PACB)?

太平洋生物科學公司(PACB)的最新分析師評級是多少？

The latest analyst rating for Pacific Biosciences (NASDAQ: PACB) was provided by Barclays, and Pacific Biosciences maintained their equal-weight rating.

太平洋生物科學公司(納斯達克代碼：PACB)的最新分析師評級由巴克萊提供，太平洋生物科學公司維持其同等權重的評級。

When is the next analyst rating going to be posted or updated for Pacific Biosciences (PACB)?

太平洋生物科學(PACB)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on September 29, 2023 so you should expect the next rating to be made available sometime around September 29, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與太平洋生物科學公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。太平洋生物科學的上一次評級是在2023年9月29日提交的，所以你應該預計下一次評級將在2024年9月29日左右的某個時候公佈。

Is the Analyst Rating Pacific Biosciences (PACB) correct?

分析師對太平洋生物科學公司(PACB)的評級正確嗎？

While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $14.00 to $9.00. The current price Pacific Biosciences (PACB) is trading at is $8.36, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的太平洋生物科學(PACB)評級維持不變，目標價在14.00美元至9.00美元之間。太平洋生物科學公司(PACB)目前的交易價格為8.36美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論